Diabetes is a very prevalent disease that, unfortunately, still has no treatment...
Iovance Biotherapeutics has had a partial clinical hold imposed by the FDA. This...
Merck KGaA has been brought on board by the Massachusetts biotechnology company ...
In a recent unveiling at the 2024 Conference on Retroviruses and Opportunistic I...
NovAliX, a specialized contract research company that is committed to facilitati...
Bispecific T-cell engagers are gaining prominence in oncology, yet this hasn’t d...
Gilead Sciences has entered an agreement with Merus for the discovery of dual tu...
The challenges and opportunities surrounding Africa becoming a clinical trials g...
The UK NICE has declined to recommend Daiichi Sankyo's Enhertu for the treatment...
Alumis secured $259m in a Series C funding round to develop its clinical-stage p...
J&J submitted a new application to the EMA for the approval of its Darzalex comb...
Discover Avacta Group's groundbreaking patent for therapeutic conjugates with ex...
AI remained one of the main talking points at CTS Europe, as the roadmap for gen...
Citius Pharmaceuticals’ CEO detailed plans to launch its lymphoma therapy Lymphi...
Sionna could have four candidates in clinical trials in 2024, amidst a cystic fi...
Merck has reported a 15.1% decline in net income attributable to shareholders to...
